Komori
Revision of earnings forecasts3001Katakura Industries Co.,Ltd.Materials and Chemicals

Notice regarding the difference between the consolidated earnings forecast and actual results for the second quarter (interim period) of the fiscal year ending December 2026, and revisions to the full-year consolidated earnings forecast

For the second quarter of the fiscal year ending December 2026, revenue was broadly in line with the forecast, while operating income, ordinary income, and interim net income exceeded the forecast. Based on these results, the full-year earnings forecasts have been revised upward, while the revenue forecast remains unchanged.

Worth reading
74In focus
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
5.5
%
Wording
Conditional
How definitive the wording is.

Revised forecast

Fiscal year ending December 2026 · Second quarter (interim period) and full yearPrevious forecast published 22 May 2026
Net SalesInterim period20,800→20,834million
+0.2%
Net SalesFull year41,100→41,100million
0.0%
Operating profitInterim period2,700→3,747million
+38.8%
Operating profitFull year5,500→5,800million
+5.5%
Ordinary incomeInterim period3,400→4,523million
+33.0%
Ordinary incomeFull year6,900→7,200million
+4.3%
Profit attributable to owners of the parentInterim period4,600→5,371million
+16.8%
Profit attributable to owners of the parentFull year7,250→7,450million
+2.8%
Net income per shareInterim period145.34→169.68yen
+16.7%
Net income per shareFull year229.07→235.27yen
+2.7%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.

Reason for the revision

Increased rental income from the real estate business, some scheduled repairs being deferred to the third quarter and beyond, strong sales of functional fibers in the textile business, and lower selling, general and administrative expenses and higher sales of certain products in the pharmaceutical business. The full-year forecasts also take into account the interim results, recent business trends, and the expectation that some repairs will be carried out in the third quarter or later.

Previous-period resultsSecond quarter: revenue of ¥20,755 million, operating income of ¥3,156 million, ordinary income of ¥3,870 million, interim net income attributable to owners of the parent of ¥3,538 million, and interim net income per share of ¥110.26. Full year: revenue of ¥40,652 million, operating income of ¥5,855 million, ordinary income of ¥7,217 million, net income attributable to owners of the parent of ¥5,763 million, and net income per share of ¥180.73.
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net SalesInterim period 20,800 / Full year 41,100 → Interim period 20,834 / Full year 41,100(Interim period 0.2 / Full year 0)
Operating profitInterim period 2,700 / Full year 5,500 → Interim period 3,747 / Full year 5,800(Interim period 38.8 / Full year 5.5)
Ordinary incomeInterim period 3,400 / Full year 6,900 → Interim period 4,523 / Full year 7,200(Interim period 33 / Full year 4.3)
Profit attributable to owners of the parentInterim period 4,600 / Full year 7,250 → Interim period 5,371 / Full year 7,450(Interim period 16.8 / Full year 2.8)
Net income per shareInterim period 145.34 / Full year 229.07 → Interim period 169.68 / Full year 235.27
Fiscal Period CoveredFiscal year ending December 2026
Period CoveredSecond quarter (interim period) and full year
Publication date of previous forecast22 May 2026
Previous-period resultsSecond quarter: revenue of ¥20,755 million, operating income of ¥3,156 million, ordinary income of ¥3,870 million, interim net income attributable to owners of the parent of ¥3,538 million, and interim net income per share of ¥110.26. Full year: revenue of ¥40,652 million, operating income of ¥5,855 million, ordinary income of ¥7,217 million, net income attributable to owners of the parent of ¥5,763 million, and net income per share of ¥180.73.
Reason for the revisionIncreased rental income from the real estate business, some scheduled repairs being deferred to the third quarter and beyond, strong sales of functional fibers in the textile business, and lower selling, general and administrative expenses and higher sales of certain products in the pharmaceutical business. The full-year forecasts also take into account the interim results, recent business trends, and the expectation that some repairs will be carried out in the third quarter or later.
Consolidated / non-consolidatedConsolidated
Items this document does not state (2)
Details and amount of extraordinary lossDividend forecast revision

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

During the interim period, earnings exceeded the forecast due to increased rental income from the real estate business, some scheduled repairs being deferred to the third quarter and beyond, strong sales of functional fibers in the textile business, and lower selling, general and administrative expenses and higher sales of certain products in the pharmaceutical business. The full-year forecasts reflect the interim results, recent business trends, and the expectation that some repairs will be carried out in the third quarter or later.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice regarding the difference between the consolidated earnings forecast and actual results for the second quarter (interim period) of the fiscal year ending December 2026, and revisions to the full-year consolidated earnings forecast | Katakura Industries Co.,Ltd. (3001) timely disclosure | Komori